"Since starting Ampyra, I have the confidence in my ability to do simple things, like keeping up? to meet friends" -Kristie

Walking With AMPYRA:
Patient Videos

AMPYRA® (dalfampridine) is the only FDA-approved medication shown to improve walking in people with MS. AMPYRA improved walking in significantly more people than placebo (sugar pill) in two clinical trials (34.8% vs. 8.3% and 42.9% vs. 9.3%). Not everyone responds to AMPYRA. Individual results may vary.

See real patient videos, before and after AMPYRA

These videos show real people with multiple sclerosis (MS) who were prescribed AMPYRA. The videos were recorded during healthcare provider office visits.

Patients in these videos had varying responses to AMPYRA. It is important to note that not everyone will respond to AMPYRA. Individual results may vary.

Patient #1
What might a possible response to AMPYRA look like?

  |  
Standard Walking Test: TIMED 25-FT WALK NOT taking AMPYRA* (Left side of video) Taking AMPYRA (Right side of video)
Time it took to walk towards the camera 12.15 sec 7.12 sec
Speed 2.06 feet/sec 3.51 feet/sec
Time it took to walk away from the camera 11.75 sec 6.84 sec
Speed 2.13 feet/sec 3.65 feet/sec

*Treatment stopped for ≥72 hours

Standard Walking Test: 2-MINUTE TIMED WALK NOT taking AMPYRA* (Left side of video) Taking AMPYRA (Right side of video)
Distance covered 195 feet 315 feet
Speed 1.63 feet/sec 2.63 feet/sec

*Treatment stopped for ≥48 hours

About this video:

This video shows an actual patient with MS who was prescribed AMPYRA. The patient shown in this video performed a timed 25-foot walk and a timed 2-minute walk, shown side by side both on and off AMPYRA. The video was recorded during a healthcare provider office visit.

NEXT: What to Expect
Print A A
Questions?

1-888-881-1918

First Step Program First Step
Program

Need help taking the first step? Find out if you are eligible for
a FREE trial of AMPYRA.
Learn More

Walk Talk Walk Talk
Email Program

Join for:
  • AMPYRA information
  • Help talking to your doctor
  • MS-related walking education
Sign up now

AMPYRA® (dalfampridine) is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.

IMPORTANT NEW SAFETY INFORMATION

Do not take AMPYRA if you are allergic to dalfampridine (4-aminopyridine), the active ingredient in AMPYRA.

IMPORTANT SAFETY INFORMATION

Do not take AMPYRA if you have ever had a seizure, or have certain types of kidney problems, or are allergic to dalfampridine (4-aminopyridine), the active ingredient in AMPYRA.

Take AMPYRA exactly as prescribed by your doctor.

You could have a seizure even if you never had a seizure before. Your chance of having a seizure is higher if you take too much AMPYRA or if your kidneys have a mild decrease of function, which is common after age 50.

Your doctor may do a blood test to check how well your kidneys are working, if that is not known before you start taking AMPYRA.

AMPYRA may cause serious allergic reactions. Stop taking AMPYRA and call your doctor right away or get emergency medical help if you have shortness of breath or trouble breathing, swelling of your throat or tongue, or hives.

AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same.

The most common adverse events for AMPYRA in MS patients were urinary tract infection, trouble sleeping, dizziness, headache, nausea, weakness, back pain, and problems with balance.

Before taking AMPYRA tell your doctor if you are pregnant or plan to become pregnant. It is not known if AMPYRA will harm your unborn baby.

Tell your doctor if you are breast-feeding or plan to breast-feed. It is not known if AMPYRA passes into your breast milk. You and your doctor should decide if you will take AMPYRA or breast-feed. You should not do both.

Please see the full Prescribing Information and Patient Medication Guide.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

AMPYRA® is a registered trademark of Acorda Therapeutics®, Inc. | AMPYRA® is marketed by Acorda Therapeutics®, Inc. and manufactured under license from Alkermes Pharma Ireland Limited (APIL), Ireland | AMPYRACONNECT™ is a trademark of Acorda Therapeutics®, Inc. | The stylized path logo is a trademark of Acorda Therapeutics®, Inc. | The stylized Acorda logo is a trademark of Acorda Therapeutics®, Inc. | © 2013 Acorda Therapeutics®, Inc. All rights reserved.

AMP2043